OncoMatch/Clinical Trials/NCT06802315
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
Is NCT06802315 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cyclophosphamide (CTX) and Fludarabine (Fludara) for acute myeloid leukemia, relapsed, adult.
Treatment: Cyclophosphamide (CTX) · Fludarabine (Fludara) · Busulfan (conditioning for ALLO Transplant) — The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (GVHD) prophylaxis will include Cyclophosphamide on Day +3 and +4, tacrolimus, and mycophenolate mofetil.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Allowed: ASXL1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: BCOR poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: EZH2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: RUNX1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: SF3B1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: SRSF2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: STAG2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: U2AF1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: ZRSR2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: KMT2A (MLL) rearrangement (MLL rearrangement except t(9;11))
Poor-risk cytogenetics: MLL rearrangement with the exception of t(9;11)
Demographics
Prior therapy
Cannot have received: radiation therapy
Exception: to >20% of bone marrow-containing areas
Patients previously received radiation to >20% of bone marrow-containing areas
Lab requirements
Kidney function
creatinine clearance <30ml/min [excluded]
Liver function
bilirubin > 2.0 mg/dl (unless due to gilbert's syndrome or hemolysis), and alt and ast > 5 x uln [excluded]
Cardiac function
left ventricular ejection fraction < 50% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois Cancer Center · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06802315 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify